Numerous recent studies indicate that PIK3CA and downstream pathways are frequently targeted by genomic amplification [23], mutation [24] or overexpression [25] in solid tumors including ovarian cancer [23], [25], [26], [27], [28], [29], [30], [31], [32]. This evidence concerns the gene PIK3CA and ovarian cancer.